MedTrace Logo

Azithromycin for Meningococcal Carriage

NCT06618534 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1120

Last updated 2025-11-10

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of azithromycin in the eradication of nasopharyngeal carriage of N. meningitidis

Conditions

  • Meningococcal Infections

Interventions

DRUG

Azithromycin

A standard dose of azithromycin (500 mg) will be delivered by oral route.

Sponsors & Collaborators

Principal Investigators

  • Paulina Rebolledo, MD, MSc · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-12
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06618534 on ClinicalTrials.gov